BamSEC and AlphaSense Join Forces
Learn More

Kymera Therapeutics Inc. – Material Contracts

NASDAQ: KYMR    
Share price (5/22/26): $78.89    
Market cap (5/22/26): $6.489 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 39 pages Kymera Therapeutics, Inc. $500,000,000 Common Stock Sales Agreement
12/34/56
EX-10.3
from 10-Q 3 pages Kymera Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy
12/34/56
EX-10.2
from 10-Q 3 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]”
12/34/56
EX-10.1
from 8-K 20 pages Registration Rights Agreement
12/34/56
EX-10.1
from 10-Q 5 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]”. Performance-Based Restricted Stock Unit Award Agreement for Company Employees Under the Kymera Therapeutics, Inc. 2020 Stock Option and Incentive Plan
12/34/56
EX-10.2
from 10-Q 39 pages Open Market Sale Agreement1
12/34/56
EX-10.1
from 10-Q 6 pages Re: Amended and Restated Collaboration and License Agreement, Dated November 15, 2022 [***] Dear Ladies and Gentlemen,
12/34/56
EX-10.1
from 8-K 1 page Amendment No. 1 to the 2020 Stock Option and Incentive Plan
12/34/56
EX-10.1
from 10-Q 3 pages Kymera Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy
12/34/56
EX-10.16
from 10-K 3 pages Re: Amended and Restated Collaboration and License Agreement, Dated November 15, 2023 - Fad Term Extension Dear Ladies and Gentlemen,
12/34/56
EX-10.13
from 10-K 82 pages Lease Agreement
12/34/56
EX-10.12
from 10-K 7 pages Second Amendment to Master Collaboration Agreement
12/34/56
EX-10.10
from 10-K 155 pages Collaboration and License Agreement Between Genzyme Corporation and Kymera Therapeutics, Inc. November 15, 2022
12/34/56
EX-10.3
from 10-K 3 pages Kymera Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy
12/34/56
EX-10
from 10-K 82 pages Lease Agreement
12/34/56
EX-10
from 10-K 7 pages Second Amendment to Master Collaboration Agreement
12/34/56
EX-10
from 10-K 155 pages Collaboration and License Agreement Between Genzyme Corporation and Kymera Therapeutics, Inc. November 15, 2022
12/34/56
EX-10
from 10-K 3 pages Kymera Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy
12/34/56
EX-10.2
from 8-K 17 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 28 pages Securities Purchase Agreement
12/34/56